HAPILA teams with Transo-Pharm to present end-to-end API expertise at CPHI Milan

Gera, Germany: – High-potency active ingredient specialist CDMO HAPILA GmbH will team with its global marketing and distribution partner Transo-Pharm Handels GmbH for Europe’s leading pharma industry event, the CPHI trade expo, returning to Milan for 2024.

HAPILA and Transo-Pharm will together stage a combined presence from their shared large stand at Booth 4B17 as part of the API Zone at the Fiera Milano.

Innovative APIs

The joint HAPILA and Transo-Pharm displays will emphasize their combined expertise in developing, manufacturing and marketing advanced APIs, such as the estrogen Estriol, that has topical, suppository and oral applications. The partners have further innovative APIs under development.

Transo-Pharm and HAPILA plan to meet several shared costumers at the show to review business strategies and further products that can be developed in partnership.

End-to-end expertise

The HAPILA stand team, including CEO Dr. Uwe Müller, Head of Development and Regulatory Compliance Manager Dr. Steffen Wittmann, Head of Quality Control Kristin Kirmße, and Project Manager Dr. Richard Nohl, will be able to explain how the company’s long-term experience in the development of API-Synthesis, purification, and particle design enables it to support customers in each phase of product development and clinical trials.

Dr. Müller commented: “We have been exhibitors at the CPHI European event for almost a decade now. This amazing expo always provides us with excellent opportunities to connect with new customers looking for a highly capable CMO or CDMO. We also love to welcome entrepreneurs who are looking for a partner for the path from API-sample through to submission of dossiers for regulatory approval.”

“It is always exciting to meet international business partners on site. We attach great importance to long-term business relationships and personal meetings are an essential part of getting to know each other and building trust. We will use the CPHI to show that HAPILA is an internationally operating CMO/CDMO,” Dr. Müller added.

About HAPILA GmbH

HAPILA GmbH is a contract developing and manufacturing organization (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and cGMP manufacture of active pharmaceutical ingredients (APIs).

HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.

It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.

The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.

All HAPILA chemical synthesis is carried out in-house at its GMP certified laboratories at Gera, Thuringia, in east-central Germany.

When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.

For more information, visit: www.hapila.de/ecom

About Transo-Pharm Handels

Founded in 1987, Transo-Pharm Handels GmbH has grown into a reliable partner in the pharmaceutical industry employing a team of highly experienced, motivated, and qualified professionals at its headquarter in Siek near Hamburg, Germany. This is a forward-thinking marketing and distribution company dedicated to quality, innovation, and global partnerships.

In 2023 alone, Transo-Pharm supplied more than 160 APIs to some 60 countries worldwide. The company prides itself on its customer-centric business model and in being able to provide tailored solutions to meet unique needs.

Since 1999, Transo-Pharm has also provided regulatory services to its customers. After 25 years, its Science & Regulatory Affairs (SRA) department now has in-depth knowledge and expertise to address technical needs, concerns, and expectations of customers from different regions.

Transo-Pharm is committed to maintain the highest levels of quality and compliance. Since the early 2000s, its ability to meet GMP standards and the ever-changing requirements of the latest pharmaceutical industry guidelines and principles have been confirmed by repeated inspections.

Learn more at: https://www.transopharm.com

About CPHI Milan 2024

Now in its 35th year, CPHI continues as the flagship European annual trade show for pharma ingredients and partner sourcing, with a refreshed mission to be the industry’s main enabler for sustainability, whilst also being an environmentally and socially responsible event.

The recently rebranded expo now uses a hybrid model that fuses one of Europe’s largest physical expos with an online dimension to make networking and browsing easier and to extend the time frame of the event indefinitely.

For 2024, CPHI Milan is a three-day event opening October 8 at the Fiera Milano convention center, with the online dimension now accessible all year round.

The newly integrated main CPHI event features exhibitor zones for Machinery & Equipment, Finished Dosage, Packaging & Drug Delivery, Contract Manufacturing & Services, APIs, Excipients, Integrated Pharma, Natural extracts, and Fine Chemicals

CPHI Milano is organised by Informa Markets with further information at: https://www.cphi.com/europe/en/home.html

Resources

Click on HAPILA at CPHI 2024 Milan to see exhibitor profile.
Click on Estriol Micronized API for further information.
Click on Transo-Pharm at CPHI Milan 2024 to see exhibitor profile.
Follow HAPILA on LinkedIn.
Follow Transo-Pharm on LinkedIn.